BIOCYTOGEN-B (02315.HK): 2025 Net Profit Surges 384%-443% Year-on-Year

NewTimeSpace News: BIOCYTOGEN-B(02315.HK) released its 2025 annual performance forecast on January 29, 2026, disclosing the preliminary financial calculation results of the full year. According to the forecast, the company is expected to achieve a revenue of RMB 1,368.8084 million to RMB 1,388.8084 million in 2025, a year-on-year increase of 39.61% to 41.65%. The growth on the profitability side is more remarkable: the net profit attributable to shareholders of the parent company is projected to reach RMB 162.4286 million to RMB 182.4286 million, a year-on-year surge of 384.26% to 443.88%.

Regarding the reasons for the substantial performance growth, BIOCYTOGEN-B stated that it mainly benefits from the continuous expansion of overseas markets coupled with the recovery and rebound of the domestic biopharmaceutical industry, driving rapid revenue growth; meanwhile, the company's high-barrier technological advantages ensure that the business gross profit remains at a high level, and lean management measures have further improved operational efficiency, promoting the rapid improvement of profitability.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.